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Background. Some patients with severe nonallergic asthma can be diﬃcult to treat with conventional therapy. Mycophenolat
Mofetil(MMF)isanimmunosuppressivedrugwithmultiplemechanisms.ThereistheoreticalsupportofspeciﬁceﬀectofMMFon
severe asthma, in “diﬃcult to treat” patients. The aim of the present case was to explore whether MMF had an eﬀect in one case of
severerefractoryasthma.Thepatient.Thiscasedealswithonepatientwithveryseverenonallergictreatmentrefractoryasthmawho
experienced treatment failure on ordinary antiasthmatic treatment and severe adverse events to conventional immunosupressive
treatment. She was then treated with MMF. Results. The patient experienced a gain in FEV1 and a reduction in the need for oral
glucocorticosteroids as well as seldom need of when needed bronchodilator both duringdaytime and night. It therefore seems very
interesting to examine the use of MMF for severe refractory asthma with further clinical studies and basic cellular trials.
Copyright © 2009 V. Backer et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Asthma is an inﬂammatory disease characterised by bron-
chialhyperresponsivenessandairwayobstruction.Fivetoten
percentof asthma patients have in spite of relevant treatment
severe asthma with chronic inﬂammation causing airway
remodelling and persistent loss of lung function [1].
TheGINAguidelinesrecommendedastepwisetreatment
approach, which at step 4 includes short-acting beta-agonist
(SABA), inhaled glucocorticosteroids (ICS) in combination
with long-acting inhaled beta2-agonist (LABA), as well as
oral theophyllin [2]. However, in severe cases with poor con-
trolled asthma, although maximally treated, additional treat-
ment with oral glucocorticosteroids (OCS) is needed [3],
even though side eﬀects of long-term treatment are health
damaging. Although, the GINA guidelines try to be covering
the entire ﬁeld, some suggest that it might be to superﬁcial
and not cover all possibilities [4].
Thus diﬀerent types of immunosuppressive drugs have
been tested [5, 6] in order to gain disease control severe
persistent asthma. The commonly used Immunomodulatory
therapy is primary Azathioprine (ATZ) or methotraxate
(MTX) [4]; however in dermatology they have shifted from
these drugs to other therapeutic possibilities with a more
acceptable proﬁle with fewer side eﬀects. One of these are
Mycophenolat Mofetil (MMF), and this drug could also be
a possible drug of choice in asthma treatment as MMF has
several immunosuppressant actions in animal models and
in “in vitro” trials: it inhibits the proliferation of T- and B-
lymphocytes, increases apoptosis in T-lymphocytes, inhibits
initiation of and suppresses ongoing immunoglobulin pro-
duction, interferes with the maturation process of dendritic
cells, inhibits the adhesion and penetration of monocytes
and T-lymphocytes by the inﬂammatory site, and inhibits
the inducible Nitric Oxide (iNOs). It is believed that T-
lymphocytes play an important role in asthma and that T-
lymphocytes resistant to corticosteroids can be suppressed
by other immunosuppressive agents, for example, by MMF
[7, 8]. Furthermore, MMF is also expected to decrease
the production of the inﬂammatory promoters TNF alpha
and Interleukin 1 [9, 10]. Besides the immunosuppressive
mechanisms, MMF seems to have an antiproliferative eﬀect,
for example, on the smooth muscle cells, endothelial cells,
and ﬁbroblasts [10], which could help preventing the airway
remodelling of severe asthma.
So far MMFhas mostly been usedfor prevention of acute
and chronic allograft rejection, but indications such as dia-
betic nephropathy (animal trials), lupus nephritis (human2 Journal of Allergy
trials), rheumatoid arthritis (human trials), ocular inﬂam-
mation (human trials), myasthenia gravis (human trials),
several skin diseases (human trials), and cytomegalovirus
infections (human trials) have been suggested [9–11].
Lastly, two studies have shown that MMF is able to
suppress inﬂammatory activity in leukocyte cultures from
asthma patients [7, 8] and seems to be relatively safe, the
main adverse events being gastrointestinal inconvenience
and mild reversible bone-marrow suppression [8–11]. How-
ever, little is known about the long-term eﬀects and side
eﬀects.
2. The Case
A 54-year-old woman, known with asthma for ten years, was
referred to a Department of Respiratory Medicine because
of severe asthma, which was diﬃcult to treat. She had a
smoking history of ﬁve packyears but had stopped ten years
before. She had no allergies, had two family members with
severe asthma, and worked as an oﬃce assistant with no
work-related toxic exposure. Her asthma had been diﬃcult
to control in spite of relevant treatment, she had had ﬁve
oral courses of glucocorticosteroid within the last six months
prior to referral to the University hospital, and she had been
on a part-time sick leave for approximately six months prior
to referral. She had gained in weight over a ten-year period
from 59kg to 110kg.
2.1. Prior to Referral. Her FEV1 had varied between 1.4L
(53%) and 1.7L (64%) in the last six months at her GP.
HerdailytreatmentincludedICS(budesonid640µg),LABA,
short acting anticholinergica, and SABA 8–12 times daily,
when needed.
2.2. At Referral. Basic evaluations were performed, such as
Chest X-ray, Electrocardiogram, Echocardiography, alpha1-
antitrypsine, and Allergy tests which all were normal. The
Computer Tomography (CT) scan showed discreet lung
emphysema, indicating hyperinﬂation.
Her lung function was measured, and FEV1 increased
from 1.35L (50%) to 1.85 (70%) after four puﬀso fb e t a 2-
agonist; the post bronchodilator FVC was 2.57 (81%) and
FEV1/FVC ratio was 92%. Initially, her ICS dose was
changedtomometasonfuroat(800µg)combinedwithLABA
twice daily and theophyllin (300mg) as well as long-acting
muscarine antagonist (LAMA) was added.
After two months of follow-up at the out-patient clinic
her lung function had further deteriorated as FEV1 was 1.22
(46%) and one month later as low as 0.96L (36%). She had
many daily asthma attacks as well as night time symptoms.
The night time awakenings due to asthma happened almost
every night. She was given a nebuliser to treat acute attacks.
Due to the further deterioration in lung function, her
t r e a t m e n tw i t hI C Sw a ss w i t c hb a c kt ob u d e s o n i d ea sw e l l
as increased in dosis and oral corticosteroid was added.
After four months of unsuccessful asthma treatment
her asthma continued to be uncontrolled. Azathioprine
(100mg) was added but after two months of treatment it was
withdrawn again due to intolerable adverse events (nausea,
vomiting, diarrhoea) and furthermore, lack of eﬀect on the
asthmatic disease. The OCS dose was during this period
ﬂuctuating between 25mg and 12.5mg daily.
After six months of follow-up, on high doses of ICS,
continued doses of OCS, theophyllin, LAMA, LABA, SABA,
and nebulised SABA when needed—still without having
controlled her asthma—we decided to start her on another
immunosuppressive treatment and we wanted to explore the
eﬀect of MMF treatment.
Prior to MMF treatment the patient had a ﬁberop-
tic bronchoscopia performed with mucosa biopsies and
bronchial lavage, she had her eNO and lung function
measured, and blood samples taken including blood cell
count, eosinophilic chemotacktic protein (ECP), and alpha-
1-antitrypsine, all of them were close to normal. On oral
corticosteroid treatment, the bronchial mucosal biopsies
were normal, apart from mild oedemas, and the lavage
ﬂuid showed few neutrophiles but no eosinophiles. Blood
leukocytes were slightly raised. All other blood samples were
normal, and eNO was not increased.
2.3. Mycophenolat Mofetil. A dose of 500mg MMF was
initiated. Within the ﬁrst week the patient’s FEV1 rose from
1.38 (52%) to 2.03 (76%) in spite of a decreased OCS dose
to 15mg daily. Her peak ﬂow increased from 284 (73%)
to 417 (107%), her symptoms diminished, her night time
symptomsdisappeared,andshehadlessneedofSABA.MMF
was further increased to 1000mg bid, and OCS was kept on
15mg daily.
Since the beginning of MMF treatment she has experi-
enced better asthma control. She has during the last year had
one exacerbation with pulmonary infection, high fever, and
deterioration in lung function, after which her MMF doses
were reduced to 750mg bid. But in general, her asthma is
now well controlled, with few asthma symptoms and hardly
any use of extra SABA. She still uses moderate doses of ICS,
LABA, and LAMA. Her FEV1 has been unchanged (60%–
70%), PEF has stabilised on 400L/sec, very few extra puﬀs
of SABA are needed, and her systemic steroid has been kept
on 5mg, and MMF on 750mg bid. Since the start of MMF
and the reduction in OCS, she has lost 20kg in weight and
have takenup her work at 50% or more. She is having few, if
any, seek leave days from work due to asthma and she have
started physical rehabilitation.
3. Discussion
This case shows an example of severe nonatopic asthma,
which was diﬃcult to control with conventional therapy due
to treatment failure and adverse events.
Drugs such as Tacrolismus, Azathioprin, Methrotraxat,
Cyclosporine, and MMF are all immunosuppressive agents
that have been suggested for the treatment of severe
refractory asthma, but none of them have been tested for
this purpose. We decided to explore the eﬀect of MMF
because it—at least in theory—seems reasonable as an
antiasthmatic treatment. Furthermore, a substantial shift toJournal of Allergy 3
MMF in dermatology, when treating severe uncontrolled
atopic eczema in adults, has occurred.
Uncontrolled asthma could besides being diﬃcult to
treat, be caused by low adherence to the antiasthmatic
treatment. Adherence is a big issue in asthma treatment,
as it is well known at least in the adolescents, and the
young adults are having an adherence rate of 40%–70%.
However the present patient had gain almost 60kg in weight
during a period of 10 years and repetitive steroid courses.
Furthermore, she has deterioration in lung function and was
threaded of losing her job, and her family was anxious of
her severe exacerbations twice a month. Although we never
in clinical practise in adult outpatients clinics count the use
of inhaled steroid puﬀs, we do believe that she was rather
adherent.
In this patient, we saw an immediate eﬀect of MMF with
ad e c r e a s ei ns u b j e c t i v es y m p t o m sa n dS A B Ar e q u i r e m e n t
as well as a substantial rise in FEV1. The basic pathology
in asthma behind this immediate eﬀect is unknown, but
knowledgefromtheuseofMMFinpreventinggraftrejection
supports a quick onset of action of the drug [9] but it is
diﬃcult to predict exactly which of the anti-inﬂammatory
mechanisms is responsible for this. We cannot explain this
immediate eﬀect, and although the mechanism behind this
is unknown, it has been a stable improvement with fewer
and minor exacerbation than prior to MMF. Furthermore,
on a longer term, the drug was able to stabilize the patients’
asthmaonasubstantiallyreduceddoseofOCS,followedbya
weightreductionof20kg,withonlyoneexacerbationduring
the year of follow-up, and there have been no detectable
adverse events.
Since this observation is based on only one case study,
it is possible that the improvement after initiating MMF is
due to an eﬀect of frequent visit and personal caretaking
or a “regression towards the mean.” It is also possible that
an increase in compliance could have played a part in the
variations of her lung function and symptoms, although
this patient was followed closely during the entire followup
period, had a good inhalation technique, and was motivated
to follow the diﬀerent treatment changes from the start.
Furthermore, Azathioprine did not show the same eﬀect but
caused adverse events in this patient. On the other hand,
during the entire period of MMF treatment there had been
no gastrointestinal side eﬀects, and furthermore no signs of
bone-marrow depression.
When the MMF treatment was initiated in this patient,
she did not have an increased level of exhaled eNO. This can
beexplainedbyherconstantOCStreatment,whichprobably
partly suppressed the inﬂammation but could also be that
thispatient hadaneutrophilic asthmawhichprobablywould
show a lower level of eNO.
From this case, no predictions regarding the long-term
eﬀects or side eﬀects of MMF, the glucocorticosteroid-
sparing ability, can be made. Nevertheless, since the theory
supports speciﬁc eﬀect of MMF, this case indicates an
eﬀect of the drug, and due to a great need for alternative
treatments, it seems interesting to examine the use of MMF
for severe refractory asthma further clinical studies and basic
cellular trials.
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